Fri, Jul 25, 2014, 2:59 AM EDT - U.S. Markets open in 6 hrs 31 mins

Recent

% | $
Click the to save as a favorite.

Allergan Inc. Message Board

voyvik11 3 posts  |  Last Activity: Jun 16, 2014 11:41 PM Member since: Jan 19, 2011
  • voyvik11 by voyvik11 Jun 16, 2014 11:41 PM Flag

    Many of you seem to feel the Valeant bid is inadequate but the stock was trading in the $130s at the time and you were not bidding it up to $180. Maybe we shareholders did not know the secret value of AGN but surely we do now, yet the stock drops daily from the inadequate offer from Valeant to an even lower price. Hmmm...If you all think it is worth $200 a share then you should be buying this grand bargain.
    Now you may love Mr. Pyott but he needs to earn a return for all shareholders even the recent ones and the ones he may not actually like; if someone else thinks they can do better, they need to pay up and they get their right to choose. You may like Mr. Pyott, trust me he will make lots of money either way, and land at a new company where maybe you can take the ride all over again. Who knows maybe Valeant will make him the CEO! BTW the dividend is an insulting low for all the non-GAAP profit AGN reports.

  • I was first introduced to Thoratec in early 2009 and was impressed. the stock was around $33. Imagine my surprise when an ex-director mentioned it today at lunch and the stock was still at $33! Did I slip into a time warp? I wondered how such a great technology could produce not shareholder returns in over 5 years, I had to look to see if the same CEO was at the helm. Yep it sure looks like it. Sometimes you really have to wonder what it takes to get a board off of its dead duff and do something.

  • Marcy l'Etoile, France - April 23, 2014
    FIRST-QUARTER 2014 BUSINESS REVIEW FIOR BIOMERIEUX
    Sales:
    • Up 7.9%, including BioFire and at constant exchange rates
    • Up 4.1% like-for-like*, in line with the target for the year
    o Continued stabilization in Western Europe, up 1.4%*
    o Sustained solid growth in North America, up 5.4%*
    • Up 3.3%, on a reported basis
    2014 objective of 3 - 5% organic sales growth maintained
    Integration of BioFire effectively underway

    Alexandre Mérieux, Chief Executive Officer, said: “During the first quarter of 2014, bioMérieux's sales rose by 4.1% at constant exchange rates and scope of consolidation, in line with our target for the year, and by 7.9% after consolidating the sales from BioFire, acquired in mid-January 2014. Sales continued to trend upwards in Europe and North America. BioFire’s FilmArray® system pursued its rapid expansion, with 55 new instruments installed since the company’s acquisition. In addition, we continued to roll out VIDAS® 3, whose application for approval was filed with Chinese authorities, and we prepared for the forthcoming market launch of our innovative new clinical microbiology platforms. Lastly, in line with our strategic plan, we are deploying a new operating organization designed to effectively meet public health challenges and our customers' needs around the world”.

    Sentiment: Buy

AGN
170.57-1.86(-1.08%)Jul 24 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.